Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Circulating Tumor DNA and Tissue Testing for Pancreatobiliary Tumors.

The study compared mutation concordance between circulating tumor DNA and tissue next-generation sequencing in advanced pancreatobiliary tumors. The abstract does not name a commercial ctDNA assay.

JAMA Network OpenPubMed 40938601DOI 10.1001/jamanetworkopen.2025.31373